29.04.2014 07:30:00 CET

SANOFI: Q1 2014 Business EPS(1) up 5.8% at CER

Paris, April 29, 2014

Q1 2014 Business EPS(1) up 5.8% at CER

Sanofi Chief Executive Officer, Christopher A. Viehbacher commented:

"The Group's financial performance in the first-quarter continued the growth trajectory that emerged at the end of 2013.  Our Business EPS(1) grew 5.8% at CER which is in line with our full-year financial guidance.  Importantly, our pipeline showed steady progress.  We presented study results for alirocumab, dupilumab, initiated the LixiLan Phase III program and announced plans to resubmit the sBLA for LemtradaTM. In addition, the first dengue vaccine Phase III study met its primary endpoint. During the next three quarters of 2014, we expect important development milestones for multiple high potential pipeline projects including ToujeoTM (U300), the Dengue vaccine, alirocumab, Cerdelga and dupilumab."

(1) See Appendix 6 for definitions of financial indicators; (2) Growth in net sales is expressed at constant exchange rates (CER) unless otherwise indicated (see Appendix 6 for a definition); (3) See page 2.

Click here to download a PDF copy of the full release